EGF and Familial prostate cancer: Similarly, PAK1/2 phosphorylation at serine 144/141 was also dose-dependently and significantly reduced up to 52.4±15.1% (p<0.05) and 48.1±11.5% (p<0.04), respectively, on AZA1 treatment of EGF-stimulated DU 145 and PC-3 cells (Figure S5), indicating that Rac1/Cdc42 inhibition blocks the PAK1 signaling pathway in these prostate cancer cells.